BioSpace News Archive

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced a key opinion leader roundtable discussion to be held on Friday, August 11, 2023, 8:00 a.m. – 9:00 a.m. ET to discuss the latest data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda that will be presented at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference on August 10, 2023.

Medtronic plc, a global leader in healthcare technology, announced that it will report financial results for its first quarter of fiscal year 2024 on Tuesday, August 22, 2023.

Applied BioMath announced they have been awarded a grant to develop a simulation platform to facilitate the prediction of optimal dose, therapeutic window, and best dosing strategy of Immunocytokines.

The FDA-approved valve consists of a catheter-based stent (called Alterra), an artificial heart valve (SAPIEN 3) and the opportunity to implant the stent and valve without the need for open-heart surgery.

More stroke patients are benefiting from life-changing treatment thanks to Brainomix’s e-Stroke AI platform, according to a recent report from the Oxford Academic Health Science Network (Oxford AHSN).

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal.

Virogentics, Inc. a wholly owned subsidiary of Enzolytics, Inc., a drug development biotech company, announced the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC.

INVO Bioscience, Inc. announced the closing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock.

MSU Health Care Laboratories, a joint venture between MSU Health Care and Grand Rapids-based private equity firm Auxo Investment Partners, has announced that operations of the laboratory will begin in mid-August.

ThermoGenesis Holdings, Inc. announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading.